Once these most recent quarterly results are finalized, they will be run through TheStreet.com Ratings' model and our ratings will be adjusted accordingly. To keep up to date on all of our ratings, visit TheStreet.com Ratings Screener.
On March 11, 2009, PDI Incorporated (PDII) reported that its net loss widened in Q4 FY08. Net loss was $16.92 million, or $1.20 per share, compared with a loss of $1.52 million, or $0.11 per share. The quarterly consensus estimate was for a loss of $0.70 per share.
Revenue dropped 22.0% to $25.40 million from $32.58 million in the same quarter of the previous year. The sales services' revenue slipped 13.0% to $21.02 million from $24.17 million, hurt by the internalization of the contract sales force by one of the long-term clients. Marketing services' revenue plunged 47.8% to $4.38 million from $8.41 million as a result of a continuing weakness in the market. The company did not realize any product commercialization revenue. However, revenue increased 10.0% in PDI's on demand service offerings.PDII announced a one-year contract renewal with a major pharmaceutical company to utilize PDI's exclusive select access team to reach pediatricians. The company expects to generate approximately $6.60 million in revenue over the contract's 12-month term. PDI and the Sequenom Center for Molecular Medicine (SCMM), a wholly owned subsidiary of Sequenom Incorporated, announced that PDI has been selected to provide the sales infrastructure to launch and commercialize SCMM's noninvasive prenatal genetic screening tests based on its SEQureDx technology. For FY08, revenue decreased 3.9% to $112.53 million from $117.13 million a year ago. Net loss widened to $34.46 million, or $2.46 per share, from $9.97 million, or $0.72 per share, in FY07. Looking ahead to FY09, PDII expects operating losses, particularly in the first half of the year, and forecasts lower interest income. The cash flow is anticipated to be negative by approximately $20.00 million.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV